Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Alterola Biotech Inc

Healthcare US ABTI

0.0051USD
0.00(0%)

Last update at 2026-06-02T20:00:00Z

Day Range

0.200.20
LowHigh

52 Week Range

0.00020.0065
LowHigh

Fundamentals

  • Previous Close 0.0051
  • Market Cap7.44M
  • Volume20
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-03-31 2023-09-30 2023-03-31 2022-09-30 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2024-03-31 2023-09-30 2023-03-31 2022-09-30 2022-03-31
Income before tax -2.37438M -1.69698M -1.69698M -6.47114M -6.47114M
Minority interest - - - - -
Net income -2.37438M -1.54246M -1.54246M -6.47113M -6.47113M
Selling general administrative 2.08M 1.65M 1.65M 4.04M 4.04M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation - - - - -
Ebit - -1.89698M -1.89698M -6.47113M -6.47113M
Ebitda - -1.69698M -1.69698M -6.47114M -6.47114M
Depreciation and amortization - 0.20M 0.20M -0.00000M -0.00000M
Non operating income net other - - - - -
Operating income -2.10832M -1.89698M -1.89698M -6.47113M -6.47113M
Other operating expenses - 1.70M 1.70M 6.47M 6.47M
Interest expense - 0.20M 0.20M 0.00000M 0.00000M
Tax provision 0.00000M - 0.00000M -0.15452M 0.00000M
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -0.15452M -0.15452M -0.00000M -0.00000M
Total revenue 0.00000M - 0.00000M 0.00000M 0.00000M
Total operating expenses 2.11M 1.70M 1.70M 6.47M 6.47M
Cost of revenue - - - - -
Total other income expense net -0.26606M 0.20M 0.20M -0.00000M -0.00000M
Discontinued operations - - - - -
Net income from continuing ops -2.37438M - -2.07119M -1.54246M -6.47119M
Net income applicable to common shares - - - -1.74246M -
Preferred stock and other adjustments - - - - -
Breakdown 2024-03-31 2023-09-30 2023-03-31 2022-09-30 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2024-03-31 2023-09-30 2023-03-31 2022-09-30 2022-03-31
Total assets 0.00366M 12.38M 12.38M 12.13M 12.13M
Intangible assets - 12.14M 12.14M 12.00M 12.00M
Earning assets - - - - -
Other current assets - 0.24M 0.24M 0.01M 0.01M
Total liab 1.33M 2.28M 2.28M 1.20M 1.20M
Total stockholder equity -1.32960M 10.10M 10.10M 10.93M 10.93M
Deferred long term liab - - - - -
Other current liab - 1.52M 0.90M 0.49M -0.04756M
Common stock - 0.81M 0.81M 0.80M 0.80M
Capital stock 1.38M - 0.81M 0.81M 0.80M
Retained earnings -12.41607M -9.57625M -9.57625M -7.97051M -7.97051M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.00265M 0.00889M 0.00889M 0.06M 0.06M
Cash and equivalents - - - - -
Total current liabilities 1.33M 2.13M 2.13M 1.20M 1.20M
Current deferred revenue - -1.26043M -1.26043M - -
Net debt 0.14M 1.41M 1.41M 0.10M 0.10M
Short term debt - 1.26M 1.26M 0.16M 0.16M
Short long term debt 0.15M - 1.26M 1.26M 0.10M
Short long term debt total - 1.41M 1.41M 0.16M 0.16M
Other stockholder equity - 18.86M 18.86M 18.08M 18.08M
Property plant equipment - - - - -
Total current assets 0.00366M 0.24M 0.24M 0.13M 0.13M
Long term investments - - - - -
Net tangible assets - - - -2.04423M -
Short term investments - - - - -
Net receivables - 0.04M 0.04M 0.05M 0.05M
Long term debt - - 0.15M 0.15M 0.16M
Inventory 0.00101M 0.00099M 0.00099M 0.00105M 0.00105M
Accounts payable - 0.61M 0.61M 0.54M 0.54M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -0.06317M -0.06317M 0.01M 0.01M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -0.18935M -0.18935M 0.01M -
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 12.14M 12.14M 12.00M 12.00M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2024-03-31 2023-09-30 2023-03-31 2022-09-30 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2024-03-31 2023-09-30 2023-03-31 2022-09-30 2022-03-31
Investments - - -0.13980M -0.13980M 0.00000M
Change to liabilities - - - 0.07M -
Total cashflows from investing activities - - -0.13980M -0.13980M -
Net borrowings 1.47M - 1.15M 1.16M -0.37833M
Total cash from financing activities 1.47M 1.21M 1.21M -0.00967M -0.00967M
Change to operating activities - - - -0.11650M -
Net income -2.37438M -1.74246M -1.74246M -6.47113M -6.47113M
Change in cash 0.02M -0.05493M -0.05493M 0.06M 0.06M
Begin period cash flow 0.00890M 0.06M 0.06M 0.00052M 0.00052M
End period cash flow 0.00265M 0.00889M 0.00889M 0.06M 0.06M
Total cash from operating activities -1.44709M -1.03979M -1.03979M 0.04M 0.04M
Issuance of capital stock 0.00000M - 0.05M 0.05M 0.37M
Depreciation - 0.14M 0.14M - -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.00002M - 0.00006M -0.00105M -0.00105M
Change to account receivables - - - -0.05069M -0.05069M
Sale purchase of stock - - - - -
Other cashflows from financing activities - 1.16M 1.16M -0.37833M -0.37833M
Change to netincome - - - 0.75M -
Capital expenditures 0.00000M 0.14M 0.14M 0.14M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.39M -0.03479M -0.03479M 0.76M 0.76M
Stock based compensation - 0.80M 0.80M 0.80M 5.76M
Other non cash items 0.54M -0.01223M -0.01223M 5.76M 5.76M
Free cash flow -1.44709M -1.17959M -1.17959M 0.04M 0.04M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ABTI
Alterola Biotech Inc		 - -% 0.0051 - - - 0.52 -3.3574
ZTS
Zoetis Inc		 1.20 1.57% 77.59 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.58 1.91% 31.01 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 153.91 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.79 1.89% 40.92 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Alterola Biotech, Inc., a pharmaceutical company, engages in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. It focuses on the development of regulated human and animal health pharmaceuticals and regulated food products; production of active pharmaceutical ingredients and food-grade ingredients; and formulation and drug delivery for improved bioavailability, solubility, and stability. Alterola Biotech, Inc. is based in Birkenhead, the United Kingdom.

Alterola Biotech Inc

47 Hamilton Square, Birkenhead, United Kingdom, CH41 5AR

Key Executives

Name Title Year Born
Mr. Timothy Paul Rogers Exec. Chairman & CFO 1964
Mr. Colin G. Stott B.Sc. COO & Director 1966
Mr. Dominic Schiller IP Counsel, Chief IP Officer & Director 1965
Mr. Hunter Land VP of Translational Research & Director 1985
Mr. Seamus McAuley Sec. & Director 1976
Mr. David Hitchcock O.B.E. CEO & Director 1963
Mr. David John Hitchcock O.B.E. Chief Executive Officer 1963
Mr. Nathan Thompson CFO & Secretary 1975

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.